Close Menu

NEW YORK (360Dx) – Paris-based Sebia said today that it has inked an agreement with Janssen Biotech to develop an in vitro diagnostic test that mitigates potential interference during immunofixation electrophoresis tests that measure a patient’s response to Darzalex (daratumumab), Janssen’s FDA-approved monoclonal antibody used to treat multiple myeloma.

Financial terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.